Difference between revisions of "Iobenguane I 131 (Azedra)"
Jump to navigation
Jump to search
(Created page with "==General information== Radioactive MIBG ==Diseases for which it was used== *Pheochromocytoma ==History of changes in FDA indication== *2018-07-30: Initial approval for...") |
m |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Generic names:''' <sup>131</sup>I-Metaiodobenzylguanidine, <sup>131</sup>I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine | + | *'''Generic names:''' <sup>131</sup>I-Metaiodobenzylguanidine, <sup>131</sup>I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine |
*'''Brand name:''' Azedra | *'''Brand name:''' Azedra | ||
Revision as of 18:32, 7 April 2023
General information
Radioactive MIBG
Diseases for which it was used
History of changes in FDA indication
- 2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. (Based on MIP-IB12B)
Also known as
- Generic names: 131I-Metaiodobenzylguanidine, 131I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine
- Brand name: Azedra